Compare KBSX & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KBSX | ACRV |
|---|---|---|
| Founded | 1976 | 2018 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.0M | 56.5M |
| IPO Year | N/A | N/A |
| Metric | KBSX | ACRV |
|---|---|---|
| Price | $1.15 | $1.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 12.4K | ★ 839.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $805.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $1.05 |
| 52 Week High | $8.75 | $6.08 |
| Indicator | KBSX | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 36.99 | 39.07 |
| Support Level | $1.16 | $1.46 |
| Resistance Level | $1.27 | $1.71 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 29.41 | 26.36 |
FST Corp is a renowned manufacturer and innovator in the golf industry with a growing portfolio of creative golf products, including acclaimed golf club shafts and other equipment. The Company has engaged in the research, development, manufacturing, and sales of golf club shafts. The Company currently produces and sells golf club shafts under the Company's own high performance KBS golf club shaft brand, and serves as an original equipment manufacturer (OEM) and original design manufacturer (ODM) for other world-renowned golf equipment brands, golf equipment OEMs, and golf equipment distributors that provide consumers with customized golf club services.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.